AI assistant
Triochem Products Ltd. Annual Report 2021
63375_rns_2021-06-29_dcca52f1-99ed-4783-842c-71c02cc26097.pdf
Annual Report
Open in viewerOpens in your device viewer
MANUFACTURERS OF ETHICAI. PHARMACEUTICAL PRODUCTS Regivtcrod office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Mcharashtra, PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2282 8181 Emall: [email protected] Website: www. triochemDroducts.com Coxporate Identity Nunbcr: L24249MH 1972PLC015 544
Rot No: TPL PP 20210338 2021; 29th]une 2021
To BSE Linuted Corporate Relationship Department, Phiroze Tcejeebhoy Towers, Dalal Street, Fort. Muimbai: 400 001. Security Code No. 512101 -ISIN No.: INE331E01013.
Dear Sir / Medap
Sub: Submission Of Audited Financial Results for the Ouarter and Year ended 31S[ March 2021
We refer to our letter dated 15th June 2021 on the captioned subject.
Pursuant to Regulation 30 and 33 Of SEBI adsting Obligations and Disclosure Requirements) Regulations, 2015, In this subject, we wish to infom you that the Board Of Director Of the Company at its meeting held toddy i.e. Tuesday, 29tb June 2021 have interalia considered and approved the Audited Financial Results Of the Company for the quartertyear ended Slat March, 2021 duly reviewed by the Audit Committee.
The said financial results, duly signed by the Director & CEO of the company along with the statutory auditor's report with unmodified opinion thereon are enclosed for your perusal and records. A declaration is given in compliance to Regulation 33@ys Of the SEBI (roDR) Regulation, 2015 as amended by the SEBI ¢ODR) (Amendment) Regulation, 2016 vide notification no. CHVCFDcOcO16 dated May 27, 2016, and notification no. SEBMAD-NRoro16-17rml dated htry 25, 2016, is also enclosed.
Also, informed that the audited financial results in prescribed fomat will be published in "Free Press ]ournal" and INavshakti" newspaper, as required. Please take the same in you record.
Thandngyou, your faithfully, For TRIOCIIEM PRODUCTS LIMITED
c,! -- RAMU S. DEORA iii-
DIRECTOR & CEO DIN: 00312369 Encl.: as al>ove
Pure Address . 123. Sohrab Hall, 21 Sassoon Road, Opp Jehangir Hospital, Pune -411001. T . 020 4906 7177 E L |[email protected] . W : "M/.kdg.co.In
Independent Auditors Report on the Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulations 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended
TO,
The Board of Directors of Tr[ochem Products Limited
Opinion
We have audited the accompanying statement of Financial Results of Triochem Products Limited ("the company") for the quarter ended March 31, 2021 and the year to date statement for the period from April 01, 2020 to March 31, 2021, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
In our opinion and to the best of our infomation and according to the explanations given to us these Financial results:
- (i) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- (ii) give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net loss and other comprehensive income and other financial information for the quarfer ended March 31, 2021 as well as the year to date statement for the period from April 01, 2020 to March 31, 2021.
Basis for Opinion
We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chaitered Accountants of India together with the ethical requirements that are relevant to our audit of the Financial Results under the provisions of the Companies Act. 2013 and the Rules thereunder, and we have fumlled our other ethical responsibilities in accordance with these requirements and the Code Of Ethics. We believe that the audit evidence we have obtained is suffroient and appropriate to provide a basis for our opinion.
Management's Responsibilities for the Financial Results
These quarterly financial results as well as the year to date financial results have been prepared on the basis Of the annual financial statements. The Company's Board of Directors are responsible for the preparation of these Financial Results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid do\^rn in Indian Accounting Standard
Kanu Doshi Associates LLP Continuation Sheet
prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuraey and completeness of the accounting records, re`evant to the preparation and presentation of the Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.
In preparing the Financial Results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis Of accounting unless the Board Of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
The Board of Directors are also responsible for overseeing the Company's financial reporting process.
Auditor's Responsibilities for the Audit of the Financial Results
Our objectives are to obtain reasonable assurance about whether the Financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Results.
As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
- ldentfty and assessthe risks of material misstatementofthe Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the ciroumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board Of Directors.
- Conclude on the appropriateness Of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the
related disclosures in the financial statement or, if such disclosures are inadequate, to
modfty our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
• Evaluate the overall presentation, structure and content of the Financial Results, including the disclosures, and whether the Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identfty during our audit.
We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.
We also performed procedures in accordance with the circular No CIR/CFD/CMD1/44rao19 issued by the SEBl under Regulation 33(8) Of the Listing Regulations, as amended, to the extent applicable.
Other Matters
The annual financial results include the results for the quarter ended 31 March 2021 being the balancing figures between the audited figures in respect of the full financial year and the published audited year to date figures up to the third quarter of the current financial year.
For Kanu Doshi Associates LLP Chartered Accountants Firm Registration No: 104746W/\/V100096
KU N A L Dlgltally slgned dy KUNAL S U MA NT E:tT2T2Y.Ao6KH2:a,I;47.co VAKHAR|A ros'3o'
Kunal Vakharia
Partner Membership No: 148916 UDIN: 21148916AAAAFD5465
Place: Mumbai Date: June 29, 2021
MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2282 8181 E-mail: [email protected] Website: www.triochemproducts.com Corporate Identity Number: L24249MH1972PLC015544
Ref No: TPL PP 20210339 2021; 29th June 2021
To BSE Limited Corporate Relationship Department, Phiroze Jeejeebhov Towers, Dalal Street, Fort, Mumbai: 400 001. Security Code No. 512101 - ISIN No.: INE331E01013
Dear Sir / Madam,
Sub: Declaration pursuant to Regulation 33(3)(d) of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements), Regulation 2015
The Board of Directors of the Company at its meeting held on 29th June, 2021 has approved the Audited Financial Results of the Company for the year ended 31st March, 2021 and we hereby declare that the Statutory Auditors of the Company, M/s. Kanu Doshi Associates LLP., Chartered Accountants, (FRN: 104746W/W100096) have issued an Audit Report with unmodified opinion thereon.
This declaration is issued in compliance with the provisions of the Regulation $33(3)(d)$ of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulation, 2015 as amended by the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) (Amendment), Regulation 2016 vide notification no. SEBI/LAD-NRO/2016-17/001 dated May 25, 2016 and Circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016.
The Declaration may kindly be taken on your records.
For TRIOCHEM PRODUCTS LIMITED
RAMU S. DEORA DIRECTOR & CEO DIN: 00312369
MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS
Registered Office: 4th Floor, Sambaya Chambers, Sir, P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657 E-mall: [email protected] Website: www.triochemproducts.com Corporate Identity Number: L24249MH1972PLC015544
TRIOCHEM PRODUCTS LIMITED Registered Office: Sambava Chambers, 4th Floor, Sir P. M. Road, Fort, Mumbai - 400 001 website: www.triochemproducts.com CIN: L24249MH1972PLC015544 AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2021 (Rs. in lakhs) Except EPS Year Ended Particulars Quarter Ended $S_{r}$ DECEMBER MARCH 31. MARCH 31. No MARCH 31, MARCH 31. 2021 31, 2020 2020 2020 2021 (Audited) (Unaudited) (Audited) (Audited) (Audited) (Refer Note (Refer Note $No. 5)$ $No. 5)$ $\mathbf{1}$ Income (a) Revenue from Operations 773.48 394.50 1.147.66 1,393.84 2.003.18 (b) Other income 7.54 0.16 33.38 13.38 46.63 Total Income from operations 781.02 394.66 1,181.04 1,407.22 2,049.81 $\overline{2}$ Expenses: (a) Cost of materials consumed $(0.00)$ 644.87 968.86 0.33 544.16 (b) Purchase of stock-in-trade 602.73 32.77 602.73 37.55 (c) Changes in inventory of finished goods, work-in-progress and stock-in-trade 125.29 360.19 251.69 13.41 354.67 (d) Employee benefits expenses 16.39 16.74 30.41 66.91 82.33 10.90 22.97 (e) Finance costs 1.37 $247$ 5.78 (f) Depreciation and amortisation expense 3.54 3.46 4.11 13.88 16.68 26.64 (g) Other expenses 37.41 21.40 112.64 111.57 Total Expenses 787.06 404.26 895.56 1,465.33 1,594.63 3 Profit / (Loss) from ordinary activities before exceptional items (1-2) $(6.04)$ $(9.60)$ 285.48 $(58.11)$ 455.18 $\overline{4}$ Exceptional items 5 Profit / (Loss) before tax $(3 + (-4))$ $(6.04)$ $(9.60)$ 285.48 $(58.11)$ 455.18 $\overline{6}$ Tax expense Current tax $(0.77)$ $(0.00)$ 73.31 $(0.75)$ 117.33 Deferred tax 0.32 $(0.63)$ $(12.66)$ $(2.42)$ $(2.43)$ Total Tax expenses $(0.45)$ $(2.42)$ 72.68 $(13.41)$ 114.90 Profit / (Loss) for the period $(5 + (-6))$ $(5.59)$ $(7.18)$ 212.80 $(44.70)$ 340.28 8 Other comprehensive income, net of income tax A. (i) Items that will be reclassified to profit or Loss (ii) Income tax relating to items that will be reclassified to profit or loss B. (i) Items that will not be reclassified to profit or Loss $(1.82)$ 0.43 0.02 $(2.34)$ $(0.30)$ (ii) Income tax relating to items that will not be reclassified to profit or loss 0.46 $(0.11)$ $(0.00)$ 0.59 0.08 Total Other comprehensive income, net of income tax $(1.36)$ 0.32 $0.02$ $(1.75)$ $(0.22)$ 212.82 $\overline{9}$ Total Comprehensive income for the period $(8 +/-7)$ $(6.95)$ $(6.86)$ $(46.45)$ 340.06 10 Paid-up equity share capital (Face value of Rs10/- per share) 24.50 24.50 24.50 24.50 24.50 11 Reserve excluding Revalution Reserves as per balance sheet of previous 1,146.69 1,193.14 accounting year 12 Earning per share (EPS) (of Rs.10/- each) (not annualised) Basic / Diluted EPS 86.86 $(2.28)$ $(2.93)$ $(18.25)$ 138.89
MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS
Registered Office: 4th Floor, Sambaya Chambers, Sir, P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001, Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657 E-mall: [email protected] Website: www.triochemproducts.com Corporate Identity Number: L24249MH1972PLC015544
PART II STATEMENT OF AUDITED ASSETS AND LIABILITIES AS AT MARCH 31, 2021 (Rs.in lakhs) Particulars As at As at $S_{r}$ March 31, March 31, No 2021 2020 Audited Audited ASSETS A 1 Non - Current Assets 86.39 97.51 (a) Property, plant and equipment (b) Capital work - in - progress 3.24 3.24 7.72 (c) Investment property 8.11 (d) Financial assets (i) Other financial assets 7.32 7.32 (e) Deferred tax assets (Net) 3.92 0.71 (f) Other non - current tax assets 7.26 (g) Other non - current assets 0.87 1.19 Sub total - Non - Current Assets 110.17 124.63 2 Current Assets (a) Inventories 85.36 155.41 (b) Financial assets 139.06 (i) Trade receivables 1.239.89 (ii) Cash and cash equivalents 819.72 55.31 (iii) Other financial assets 0.65 0.59 (c) Other tax assets (net) 33.17 ×, (d) Other current assets 22.07 85.85 Sub total - Current Assets 1,100.03 1,537.05 Total - Assets 1,210.20 1,661.68 B EQUITY AND LIABILITIES EQUITY (a) Equity share capital 24.50 24.50 (b) Other Equity 1.146.69 1,193.14 Total - Equity 1,171.19 1.217.64 LIABILITIES 1 Non Current Liabilities (a) Deferred tax liabilities (Net) 9.33 Sub total - Non- Current Liabilities $9.33$ $\overline{\phantom{a}}$ 2 Current liabilities (a) Financial liabilities (i) Borrowings 250.30 (ii) Trade payables 32.44 74.01 (b) Other financial liabilities 13.93 (c) Other current liabilities 0.93 79.86 (c) Provisions 5.64 9.05 (d) Current tax liabilities (Net) 7.56 Sub- total - Current Liabilities 39.01 434.71 Total - Liabilities 39.01 444.04 Total - Equity and Liabilities 1,210.20 1,661.68
MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS
Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657 E-mall: [email protected] Website: www.triochemproducts.com Corporate Identity Number: L24249MH1972PLC015544
CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH. 2021
| (Rs.in lakhs) | ||
|---|---|---|
| Particulars | Year Ended | |
| March 31, | March 31, | |
| 2021 | 2020 | |
| Audited | Audited | |
| CASH FLOW FROM OPERATING ACTIVITIES A |
||
| Net Profit before tax and Extraordinary Items | (58.11) | 455.18 |
| Adjustment for: | ||
| Depreciation / Amortisation | 13.88 | 16.68 |
| Interest Income | (2.64) | (0.66) |
| Reclassification of remeasurement of employee benefits | (2.34) | (0.30) |
| Interest Expenses | 10.89 | 20.06 |
| Investment Expenses | 0.04 | 0.05 |
| Sundry balance Off | (5.65) | (0.00) |
| Operating Profit before Working Capital Changes | (43.93) | 491.01 |
| Adjustments for Working Capital Changes | 64.10 | |
| Increase/Decrease in Assets | 70.05 | (33.08) 802.03 |
| Changes in Inventories Increase/Decrease Trade Receivable |
1,100.83 | (906.88) |
| Increase/Decrease in other financial and non-financial assets | ||
| Increase/Decrease Trade payables | (41.58) | 39.88 |
| Increase/Decrease in other financial and non-financial liabilities | (13.93) | 11.88 |
| Increase/Decrease in Liabilities | (78.93) | 78.62 |
| Changes in Provision | 2.24 | 0.20 |
| Cash Generated from Operations | 1,058.85 | 483.66 |
| Direct taxes paid / (refund) | (33.41) | (101.40) |
| Net Cash from Operating Activities | 1,025.44 | 382.26 |
| B CASH FLOW FROM INVESTING ACTIVITIES |
||
| Purchase of Fixed Assets including Capital Work in Progress | (2.37) | (3.24) |
| Investment Expenses | (0.04) | (0.04) |
| Interest Received | 2.57 | 0.60 |
| Net Cash Used in Investing Activity | 0.16 | (2.68) |
| CASH FLOW FROM FINANCING ACTIVITIES | ||
| Net (Decrease)/ Increase in Short Term Borrowings | (250.30) | (329.11) |
| Interest Paid | (10.89) | (20.06) |
| Net Cash Used in Financing Activity | (261.19) | (349.17) |
| NET CHANGES IN CASH & CASH EQUIVALENTS (A+B+C) | 764.41 | 30.41 |
| OPENING BALANCE OF CASH & CASH EQUIVALENTS | 55.31 | 24.90 |
| CLOSING BALANCE OF CASH & CASH EQUIVALENTS | 819.72 | 55.31 |
Notes:
1) The above audited financial results of the Company for the quarter and year ended March 31, 2021 have been reviewed by the Audit committee of the Board and approved by the Board of Directors at its meeting held on June 29, 2021
MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS
Registered Office: 4th Floor, Sambaya Chambers, Sir, P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001, Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657 E-mall: [email protected] Website: www.triochemproducts.com Corporate Identity Number: L24249MH1972PLC015544
2) The Audited financial results have been prepared in accordance with Indian Accounting Standards (Ind AS), the provisions of the Companies Act, 2013 (the Act), as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI).
- 3) The company has adopted Ind AS 116 effective period beginning from April 01, 2019. The effect of adoption of Ind AS 116 on the financial results is insignificant
- 4) The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (Ind AS-108) "Segment Reporting" is not applicable.
- 5) The figure for quarter ended March 31, 2021 and March 31, 2020 are the balancing figures between audited figures of the full financial year and the reviewed year-to-date figures up to the third quarter of the relevant financial year.
- 6) The Company's operations for the financial year have been impacted by the lockdown imposed to contain the spread of Covid-19. The Management of the Company has assessed the impact of the pandemic on its financial results/position such as trade receivables, investments, inventories, trade payables and based on its best judgement and reasonable estimate, has concluded that there are no material adjustments required in the Financial Statements. However the impact assessment of Covid-19 is a continuous process, given the uncertainties associated with its duration and nature, it is not possible to estimate the future impact as at the date of approval of this financial statement. The Company continues to monitor the economic effects of the pandemic while taking steps to improve its execution efficiencies and the financial outcome.
- 7) The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the company towards Provident Fund and Gratuity. The Ministry of Labour and Employment has released draft rules for the Code on Social Security, 2020 on November 13, 2020, and has invited suggestions from stakeholders which are under active consideration by the Ministry. The Company will assess the impact and its evaluation once the subject rules are notified and will give appropriate impact in its financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published.
- 8) The Corresponding figures of the previous quarter / year have been regrouped, recasted and reclassified to make them comparable wherever necessary.
FOR TRIOCHEM PRODUCTS LIMITED
RAMU S. DEORA
DIN: 00312369
DIRECTOR & CEO
Place: Mumbai Dated: 29th June, 2021
Page 4 of 4
9
MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS
Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657 E-mall: [email protected] Website: www.triochemproducts.com Corporate Identity Number: L24249MH1972PLC015544
| TRIOCHEM PRODUCTS LIMITED | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Registered Office: Sambava Chambers, 4th Floor, Sir P. M. Road, Fort, Mumbai - 400 001 | |||||||||
| website: www.triochemproducts.com | |||||||||
| CIN: L24249MH1972PLC015544 | |||||||||
| (Rs. in lakhs - except otherwise stated) | |||||||||
| Extract of statement of Audited Financial Results for the Quarter and Year Ended 31st March, 2021 | |||||||||
| Sr | Particulars | For the | For the | For the | For the | For the | |||
| No | Quarter | Quarter | Quarter | Year Ended | Year Ended | ||||
| Ended on | Ended on | Ended on | on | on | |||||
| 31-Mar-21 | 31-Dec-20 | 31-Mar-20 | 31-Mar-21 | 31-Mar-20 | |||||
| Audited | Unaudited | Unaudited | Audited | Audited | |||||
| 1 | Total Income from operations | 781.02 | 394.66 | 1,181.04 | 1,407.22 | 2,049.81 | |||
| $\overline{2}$ | Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items) |
(6.04) | (9.60) | 285.48 | (58.11) | 455.18 | |||
| 3 | Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items) |
(6.04) | (9.60) | 285.48 | (58.11) | 455.18 | |||
| 4 | Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items) |
(5.59) | (7.18) | 212.80 | (44.70) | 340.28 | |||
| 5 | Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and other Comprehensive Income (after tax)] |
(1.36) | 0.32 | 0.02 | (1.75) | (0.22) | |||
| 6 | Equity share capital (Face value Rs. 10/- per share) | 24.50 | 24.50 | 24.50 | 24.50 | 24.50 | |||
| Other Equity | 1,146.69 | 1,193.14 | |||||||
| 8 | Earnings per share (of Rs.10/- each) (for continuing and discontinued operations) |
||||||||
| a) Basic (not annualized) | (2.28) | (2.93) | 86.86 | (18.25) | 138.89 | ||||
| b) Diluted (not annualized) | (2.28) | (2.93) | 86.86 | (18.25) | 138.89 | ||||
| Notes: | |||||||||
| $\overline{a}$ $\cdot$ 1.7.6 $\mathbf{r}$ . |
1) The above audited financial results of the Company for the quarter and year ended March 31, 2021 have been reviewed by the Audit committee of the Board and approved by the Board of Directors at its meeting held on June 29, 2021.
2) The Audited financial results have been prepared in accordance with Indian Accounting Standards (Ind AS), the provisions of the Companies Act, 2013 (the Act), as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI).
3) The company has adopted Ind AS 116 effective period beginning from April 01, 2019. The effect of adoption of Ind AS 116 on the financial results is insignificant.
4) The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (Ind AS-108) "Segment Reporting" is not applicable.
5) The figure for quarter ended March 31, 2021 and March 31, 2020 are the balancing figures between audited figures of the full financial year and the reviewed year-to-date figures up to the third quarter of the relevant financial year.
MANUFACTURERs OF ETHlcAL plIARMACEuncAI. pRODuors Rqctstered Office. 4th Floor, Sambava Chambers, Sir. P. M Road Fort MumbaL, Maharashtra, PIN: 4()()001. Tclcohone. On 91 /22) 2266 +I 50 Fax: 00 91 (22) 2202 4657 I-mall: infolaami>hrnv com Website: www.trioche"]roducts com C,or"untc ldenthy Number: 124249MH 1972l'LC015544
- 6)T8)9) The Company's operations for the financial year have been impacted by the lockdown inposed to contain the spread o Covid.19. The Management of the Company has assessed the impact of the pandendc on its financial results/position such as trade rccciwhles, investments, inventories, trade payables and based on its best judgement and reasonal)le estinate, has concluded that there are no material edjusments required in the Financial Statements. However the inpact assessment of Covid-19 is a continuous process, given the uncertainties associated with its duration and nature, it is not possible to estimate the future impact as at the date of approval of this financial statement. The Company continues to monitor the economic cffccts of the pandemic while taking steps to improve its cxecution efficiencies and the financial outcome.
- The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the company towards Provident Fund and Gratuity. The Ministry Of labour and linpLoyment has released draft rules for the Code on Social Security, 2020 on November 13, 2020, and has invited suggestions from stakeholders which arc under active consideration by the Ministry. The Company will assess the impact and its evaluation once the subject rules are notified and win give appropriate inpact in its financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published.
- The Corresponding figures of the previous quarter / year have been regrouped, recasted and recLassified to make them comparable wherever necessary.
- The above is an extract of the detailed fomat of financial results filed with the Stock Exchange under Regulation 33 o the SEBI qisting and Other Disclosure Requirements) Regulation, 2015. The fun format of cousolidated financial results ae available on the Stock Exchange website, www.bseindia.com and on the Company's website ~.triochemproducts.com
FOR TRIOCIIEM PRODUCTS LIMITED
Place: Mumbal DIRECTOR a CEO
i-RAVS,D mted: 29thTune, 2021 DIN: 00312369
